| Literature DB >> 29390932 |
Daryl Tan1,2, Jae Hoon Lee3, Wenming Chen4, Kazuyuki Shimizu5, Jian Hou6, Kenshi Suzuki7, Weerasak Nawarawong8, Shang-Yi Huang9, Chor Sang Chim10, Kihyun Kim11, Lalit Kumar12, Pankaj Malhotra13, Wee Joo Chng14,15, Brian Durie16.
Abstract
Predicated on our improved understanding of the disease biology, we have seen remarkable advances in the management of multiple myeloma over the past few years. Recently approved drugs have radically transformed the treatment paradigm and improved survivals of myeloma patients. The progress has necessitated revision of the diagnostic criteria, risk-stratification and response definition. The huge disparities in economy, healthcare infrastructure and access to novel drugs among different Asian countries will hinder the delivery of optimum myeloma care to patients managed in resource-constrained environments. In the light of the tremendous recent changes and evolution in myeloma management, it is timely that the resource-stratified guidelines from the Asian Myeloma Network be revised to provide updated recommendations for Asia physicians practicing under various healthcare reimbursement systems. This review will highlight the most recent advances and our recommendations on how they could be integrated in both resource-abundant and resource-constrained facilities.Entities:
Keywords: Myeloma; novel agents; resource-stratified
Mesh:
Substances:
Year: 2018 PMID: 29390932 DOI: 10.1080/10428194.2018.1427858
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022